东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06887 东阳光药

已收盘 04-15 16:08:08

44.180

+0.400

+0.91%

最高44.460	最低43.800	成交量5.40万
今开43.900	昨收43.780	日振幅1.51%
总市值254.48亿	流通市值49.48亿	总股本5.76亿
成交额238.58万	换手率0.05%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":44.18,"timestamp":1776240488007,"preClose":43.78,"halted":0,"volume":54027,"delay":0,"changeRate":0.009136592051164882,"floatShares":112000000,"shares":576000000,"eps":2.080908,"marketStatus":"已收盘","change":0.4,"latestTime":"04-15 16:08:08","open":43.9,"high":44.46,"low":43.8,"amount":2385832,"amplitude":0.015075,"askPrice":44.24,"askSize":900,"bidPrice":44.16,"bidSize":300,"shortable":3,"etf":0,"ttmEps":0.524,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":43.78,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":0.350606,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887","defaultTab":"news","newsList":[{"id":"2627285608","title":"东阳光药(06887.HK)4月15日耗资5.3万港元回购1200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285608","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627285608?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:37","pubTimestamp":1776249421,"startTime":"0","endTime":"0","summary":"格隆汇4月15日丨东阳光药(06887.HK)公告，4月15日耗资5.3万港元回购1200股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260415/32145696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138875895","title":"东阳光药：4月15日回购1,200股，耗资约5.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138875895","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138875895?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:18","pubTimestamp":1776248292,"startTime":"0","endTime":"0","summary":"东阳光药(06887)于2026年4月15日公告，宣布在香港联交所场内回购1,200股H股，占公司已发行股本约0.0011%。回购价格介乎每股43.80港元至44.24港元，合计支付约5.30万港元。\n回购完成后，公司已发行股本约为112,047,732股，库存股数量增至665,100股。该次回购依据2025年12月16日通过的购回授权展开，根据授权可回购的总规模为57,665,604股，公司迄今累计已回购665,100股。\n公司确认已遵守香港联交所主板上市规则及相关法例。本次公告由公司董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115094263","title":"东阳光药4月14日回购2,500股股份，涉资约11.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115094263","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115094263?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:33","pubTimestamp":1776162792,"startTime":"0","endTime":"0","summary":"东阳光药于2026年4月14日发布公告，称公司当日在香港联交所场内回购2,500股H股。该回购股份占公司已发行股本约0.0022%，回购价格介乎每股港币43.98元至44.42元，涉资约港币11.06万元。本次回购完成后，公司已发行股本总数仍为112,712,832股，其中非库藏股112,048,932股，库藏股增至663,900股。公司披露，其回购授权于2025年12月16日通过，授权回购股份总数为57,665,604股。公告由董事张英俊签署，公告日期为2026年4月14日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417363","title":"东阳光药(06887)4月14日斥资11.06万港元回购2500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417363","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627417363?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:26","pubTimestamp":1776162414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月14日，该公司斥资11.06万港元回购2500股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626348171","title":"东阳光药于4月10日斥资10.51万港元回购2400股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626348171","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626348171?lang=zh_cn&edition=full","pubTime":"2026-04-12 14:35","pubTimestamp":1775975700,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　东阳光药（06887）发布公告，于2026年4月10日，该公司斥资10.51万港元回购2400股股份，每股回购价43.5-43.98港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-12/doc-inhufkka6618491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189012981","title":"东阳光药4月10日回购2,400股，耗资约10.51万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189012981","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189012981?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:33","pubTimestamp":1775817183,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月10日发布公告，披露近期在香港联交所进行股份回购的情况。根据公告，2026年4月10日公司于场内回购2,400股H股股份，占回购前已发行股本约0.0021%。回购价格介乎每股43.50港元至43.98港元，总耗资约10.51万港元。公告显示，公司已于2025年12月16日获股东大会批准购回授权，可回购股份总数为57,665,604股。截至本次回购后，已根据该授权于市场合计回购661,400股，占授权额度约0.1147%。此次公告由公司董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626991411","title":"东阳光药(06887)4月10日斥资10.51万港元回购2400股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626991411","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626991411?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:27","pubTimestamp":1775816863,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月10日，该公司斥资10.51万港元回购2400股股份，每股回购价43.5-43.98港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138733519","title":"东阳光药4月9日回购4000股股份，涉资约17.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138733519","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138733519?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:27","pubTimestamp":1775726827,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月9日发布翌日披露报表，公告显示当日在香港联交所回购4000股股份，涉资约17.50万港元。根据公告，此次回购股份占公司现有已发行股本约0.0036%，每股回购价介乎43.46港元至44.06港元，合计支付175,022港元。截至目前，东阳光药已累计回购659,000股，占授权通过当日公司已发行股本的约0.1143%。公司确认已遵守香港联交所主板上市规则及相关法律规定。本次公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194810157","title":"东阳光药4月8日回购4,600股，耗资约20.23万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194810157","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194810157?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:15","pubTimestamp":1775646944,"startTime":"0","endTime":"0","summary":"2026年4月8日，东阳光药(06887)公告称，于当日在香港联交所场内回购4,600股H股，占当日已发行股本约0.0041%。回购价格介乎每股43.76港元至44.42港元，涉资约20.23万港元。回购完成后，公司已发行股本变更为112,057,832股，库藏股数增至655,000股。\n公司此前于2025年12月16日通过股份购回授权，授权购回股份总数为57,665,604股。截至目前，公司累计购回655,000股，占购回授权通过当日已发行股本的约0.1136%。公告同时确认本次回购符合相关上市规则和法例。公告由董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625943443","title":"东阳光药(06887)4月8日耗资约20.23万港元回购4600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625943443","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625943443?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:12","pubTimestamp":1775646772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)公布，2026年4月8日耗资约20.23万港元回购4600股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药(06887)4月8日耗资约20.23万港元回购4600股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625472912","title":"东阳光药(06887)：富马酸伏诺拉生氯化钠注射液的药品上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2625472912","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625472912?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:42","pubTimestamp":1775641373,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，近日，本公司改良型新药富马酸伏诺拉生氯化钠注射液的药品上市许可申请获得中国国家药品监督管理局受理，申报适应症为：用于治疗消化性溃疡出血。研究结果表明，富马酸伏诺拉生氯化钠注射液可有效控制消化性溃疡出血患者的再出血风险，并具有良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126832598","title":"东阳光药：富马酸伏诺拉生及氯化钠注射液上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1126832598","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126832598?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:42","pubTimestamp":1775641332,"startTime":"0","endTime":"0","summary":"东阳光药宣布，其研发的富马酸伏诺拉生与氯化钠注射液联合用药的上市许可申请，已正式获得中国国家药品监督管理局的受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157485","title":"东阳光药大幅扭亏为盈，大湾区AI引擎深度赋能药企转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157485","media":"南方都市报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157485?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:28","pubTimestamp":1775046480,"startTime":"0","endTime":"0","summary":"3月31日，总部位于广东东莞的东阳光药（06887.HK）披露2025年年报。全年实现营收48.15亿元，较上年同期增长19.81%，归母净利润达2.72亿元，实现大幅扭亏为盈。财报显示，东阳光药积极布局“AI+创新药”战略方向，以与大湾区多家AI科技企业深度合作等方式，推进AI技术在药物发现、筛选等多个核心研发环节深度赋能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692173576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159983","06887","AIPO","AGIX","BK1191","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155560713","title":"东阳光药：4月1日回购2.49万股，耗资约109.03万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155560713","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155560713?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:15","pubTimestamp":1775045744,"startTime":"0","endTime":"0","summary":"东阳光药(06887)于2026年4月1日公告，公布当日回购2.49万股普通股，占公司已发行股本约0.0222%，回购价格介乎每股43.30港元至43.98港元，涉资约109.03万港元。\n本次回购完成后，公司已发行股本(不包括库藏股)变动为112,064,132股，库藏股数增至648,700股。公司回购授权获通过日期为2025年12月16日，根据该授权可回购股份总数为57,665,604股。截至目前，基于该授权已合计在市场购回648,700股。公司确认已遵守香港联交所主板上市规则与相关法规，公告由董事张英俊签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624132165","title":"东阳光药(06887)4月1日斥资109.03万港元回购2.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624132165","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624132165?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:15","pubTimestamp":1775045729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药(06887)发布公告，于2026年4月1日斥资109.03万港元回购2.49万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196649430","title":"东阳光药3月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1196649430","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196649430?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:11","pubTimestamp":1775045484,"startTime":"0","endTime":"0","summary":"东阳光药于2026年4月1日发布2026年3月股份变动月报。公告显示，截至2026年3月31日，公司H股及内资股已发行及注册股本均无新增发行或变动，股本结构保持稳定。根据公告，本月底H股法定注册股本为112,712,832股，内资股法定注册股本为463,943,215股，两者合计注册股本576,656,047股。公告同时披露，公司确认截至2026年3月31日，已符合适用的香港联交所公众持股量要求，并遵守相关法律法规。该月报由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623168302","title":"东阳光药(06887)公布2025年业绩 权益股东应占溢利约2.72亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2623168302","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623168302?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:10","pubTimestamp":1774948244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 公布2025年业绩，营业额为约48.15亿元，同比增加19.81%。公司权益股东应占溢利约2.72亿元，同比扭亏为盈;每股盈利0.56元。公告称，业绩增长主要由于2025年下半年流感疫情同比显著高发，集团核心产品磷酸奥司他韦作为流感防治首选药物，凭借确切的疗效、良好的品牌口碑，市场需求大幅增加，全年实现营业额35.76亿元，较2024年增长38.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620464962","title":"东阳光药(06887.HK)3月31日举行董事会会议审议及批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620464962","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620464962?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:57","pubTimestamp":1773914223,"startTime":"0","endTime":"0","summary":"格隆汇3月19日丨东阳光药(06887.HK)宣布，董事会会议将于2026年3月31日(星期二)举行，藉以(其中包括)审议及批准公司及其附属公司截至2025年12月31日止年度的年度业绩及其发布，以及考虑派付末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260319/32081854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619043391","title":"港股异动 | 东阳光药(06887)盈喜后涨超3% 预期年度归母净利约2.7亿元 磷酸奥司他韦市场需求大幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2619043391","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619043391?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:35","pubTimestamp":1773632142,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东阳光药盈喜后涨超3%，截至发稿，涨3.01%，报43.1港元，成交额649.64万港元。消息面上，3月13日，东阳光药发布公告，截至2025年12月31日止年度，集团预期取得归母净利润约为人民币2.7亿元，相较去年同期取得归母净亏损约为人民币2.1亿元增加约228.57%。预期上述增加主要由于2025年下半年流感疫情同比显着高发，集团核心产品磷酸奥司他韦作为流感防治首选药物，凭借确切的疗效、良好的品牌口碑，市场需求同比大幅增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","VXUS","06887","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619196638","title":"东阳光药(06887)发盈喜，预期2025年度归母净利润约2.7亿元 同比转亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2619196638","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619196638?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:38","pubTimestamp":1773398337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，截至2025年12月31日止年度，集团预期取得归母净利润约为人民币2.7亿元，相较去年同期取得归母净亏损约为人民币2.1亿元增加约228.57%。预期上述增加主要由于2025年下半年流感疫情同比显着高发，集团核心产品磷酸奥司他韦作为流感防治首选药物，凭借确切的疗效、良好的品牌口碑，市场需求同比大幅增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药(06887)发盈喜，预期2025年度归母净利润约2.7亿元 同比转亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":0.0464},{"period":"3month","weight":0.0167},{"period":"6month","weight":-0.0936},{"period":"1year","weight":-0.2732},{"period":"ytd","weight":-0.0399}],"compareEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.208},{"period":"ytd","weight":0.0094}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药，亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威（磷酸奥司他韦），用于治疗流行性感冒（特别是甲型及乙型流行性感冒病毒），东卫恩（磷酸依米他韦），用于治疗丙型肝炎，及主要用于治疗敏感细菌引起的感染的仿制药，即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病，包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}